CDKN2A and neoplasm: The tumor tissues were subjected to whole exome sequencing (WES) and four mutations with potential clinical significance were identified: CDKN2A deletion, CDK6 amplification, PIK3CA amplification, and KRAS G12V mutation (Figure 4B).